A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia

This study is comparing a chemotherapy drug called Elacytarabine against other standard chemotherapy options for people with late-stage acute myeloid leukaemia (AML) — a type of blood cancer — that has come back or has not responded to previous treatment. Elacytarabine works differently from standard treatments and may work even when cancer cells have become resistant to other chemotherapy drugs. Participants will be randomly assigned to one of the two treatment groups. You may be eligible if: - You are 18 years or older - You have confirmed AML that has been treated with two or three previous chemotherapy regimens without achieving lasting remission - Your cancer is currently active in the bone marrow or blood You may NOT be eligible if: - You have significant ongoing side effects from previous chemotherapy - You have serious liver or kidney problems - You have active, uncontrolled heart disease - You have received anti-leukaemia treatment within the past 4 weeks Talk to your doctor about whether this trial might be right for you.